ResearcherZhengzhou UniversityActive in the last 2 years

Yuyuan Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0972-4537; OpenAlex author ID A5100769052. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 4

Pharmacogenomics-based subtype decoded implications for risk stratification and immunotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1186/s10020-024-01049-6 ↗
Co-alteration of Myc and RTK-RAS pathways defines a liver-metastatic propensity and immune-cold subgroup of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gendis.2023.05.006 ↗
Crosstalk between regulated cell death and immunity in redox dyshomeostasis for pancreatic cancer. First author DOI 10.1016/j.cellsig.2023.110774 ↗
Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratification and frontline therapies in pancreatic … Co-author DOI 10.1016/j.csbj.2022.02.031 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xinwei Han · 4 shared papers, 2022–2025 · strength 0.74
Peng Luo · 2 shared papers, 2024–2025 · strength 0.43
- Paper Pharmacogenomics-based subtype decoded implications for risk stratification and immunotherapy in pancreatic adenocarcin… DOI 10.1186/s10020-024-01049-6 ↗
- Paper Co-alteration of Myc and RTK-RAS pathways defines a liver-metastatic propensity and immune-cold subgroup of pancreatic … DOI 10.1016/j.gendis.2023.05.006 ↗
Libo Wang · 2 shared papers, 2022–2025 · strength 0.37
- Paper Pharmacogenomics-based subtype decoded implications for risk stratification and immunotherapy in pancreatic adenocarcin… DOI 10.1186/s10020-024-01049-6 ↗
- Paper Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratificatio… DOI 10.1016/j.csbj.2022.02.031 ↗
Xing Zhou · 1 shared paper, 2025 · strength 0.22
- Paper Pharmacogenomics-based subtype decoded implications for risk stratification and immunotherapy in pancreatic adenocarcin… DOI 10.1186/s10020-024-01049-6 ↗
Jian Zhang · 1 shared paper, 2024 · strength 0.21
- Paper Co-alteration of Myc and RTK-RAS pathways defines a liver-metastatic propensity and immune-cold subgroup of pancreatic … DOI 10.1016/j.gendis.2023.05.006 ↗
Zhaokai Zhou · 1 shared paper, 2023 · strength 0.16
- Paper Crosstalk between regulated cell death and immunity in redox dyshomeostasis for pancreatic cancer. DOI 10.1016/j.cellsig.2023.110774 ↗
Jianguo Wen · 1 shared paper, 2023 · strength 0.16
- Paper Crosstalk between regulated cell death and immunity in redox dyshomeostasis for pancreatic cancer. DOI 10.1016/j.cellsig.2023.110774 ↗
Rongtao Zhu · 1 shared paper, 2022 · strength 0.15
- Paper Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratificatio… DOI 10.1016/j.csbj.2022.02.031 ↗
Weijie Wang · 1 shared paper, 2022 · strength 0.15
- Paper Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratificatio… DOI 10.1016/j.csbj.2022.02.031 ↗
Yuling Sun · 1 shared paper, 2022 · strength 0.15
- Paper Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratificatio… DOI 10.1016/j.csbj.2022.02.031 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.